Department of Medical Genetics, College of Medicine, University of Arkansas for Medical Sciences , Little Rock, AR , USA.
Drug Metab Rev. 2013 Nov;45(4):415-22. doi: 10.3109/03602532.2013.835621. Epub 2013 Sep 6.
Cytosolic sulfotransferases (SULTs) are phase II detoxification enzymes that are involved in the biotransformation of a wide variety of structurally diverse endo- and xenobiotics. Single-nucleotide polymorphisms (SNPs) in SULTs can alter the phenotype of the translated proteins. SNPs in some SULTs are fairly uncommon in the population, but some, most notably for SULT isoform 1A1, are commonly found and have been associated with cancer risk for a variety of tumor sites and also with response to therapeutic agents. SNPs in many SULTs vary by ethnicity, another factor that could influence SULT-associated disease risk and pharmacogenetics. This review surveys the current knowledge of SULT genetic variability in relation to cancer risk and response to therapy, focusing primarily on SULT1A1.
细胞溶质磺基转移酶 (SULTs) 是 II 相解毒酶，参与广泛的结构多样的内源性和外源性物质的生物转化。SULTs 中的单核苷酸多态性 (SNP) 可以改变翻译蛋白的表型。一些 SULTs 的 SNP 在人群中相当罕见，但有些 SNP 则很常见，特别是 SULT 同工型 1A1，它们与多种肿瘤部位的癌症风险以及对治疗药物的反应有关。许多 SULTs 的 SNP 因种族而异，这是另一个可能影响 SULT 相关疾病风险和药物遗传学的因素。这篇综述调查了与癌症风险和治疗反应相关的 SULT 遗传变异性的最新知识，主要集中在 SULT1A1 上。
